

AI-Assisted *In Situ* Detection of Human Glioma Infiltration Using a Novel Computational Method for Optical Coherence Tomography



Ronald M. Juarez-Chambi¹, Carmen Kut², Jose J. Rico-Jimenez¹, Kaisorn L. Chaichana³, Jiefeng Xi², Daniel U. Campos-Delgado⁴, Fausto J. Rodriguez⁵, Alfredo Quinones-Hinojosa³, Xingde Li², and Javier A. Jo⁶

Abstract

Purpose: In glioma surgery, it is critical to maximize tumor resection without compromising adjacent noncancerous brain tissue. Optical coherence tomography (OCT) is a noninvasive, label-free, real-time, high-resolution imaging modality that has been explored for glioma infiltration detection. Here, we report a novel artificial intelligence (AI)-assisted method for automated, real-time, *in situ* detection of glioma infiltration at high spatial resolution.

Experimental Design: Volumetric OCT datasets were intraoperatively obtained from resected brain tissue specimens of 21 patients with glioma tumors of different stages and labeled as either noncancerous or glioma-infiltrated on the basis of histopathology evaluation of the tissue specimens (gold standard). Labeled OCT images from 12 patients were used as the training dataset to develop the AI-assisted OCT-based method for automated detection of glioma-infiltrated brain tissue. Unlabeled OCT images from the other 9 patients

were used as the validation dataset to quantify the method detection performance.

Results: Our method achieved excellent levels of sensitivity (~100%) and specificity (~85%) for detecting glioma-infiltrated tissue with high spatial resolution (16 μm laterally) and processing speed (~100,020 OCT A-lines/second).

Conclusions: Previous methods for OCT-based detection of glioma-infiltrated brain tissue rely on estimating the tissue optical attenuation coefficient from the OCT signal, which requires sacrificing spatial resolution to increase signal quality, and performing systematic calibration procedures using tissue phantoms. By overcoming these major challenges, our AI-assisted method will enable implementing practical OCT-guided surgical tools for continuous, real-time, and accurate intraoperative detection of glioma-infiltrated brain tissue, facilitating maximal glioma resection and superior surgical outcomes for patients with glioma.

Introduction

Gliomas are the most common and aggressive primary brain cancers in adults (1, 2). It is well established that maximal glioma surgical resection can lead to both prolonged survival and delayed cancer recurrence (1, 3–6). The challenge, however, lies in the limited ability of neurosurgeons to differentiate cancerous versus noncancerous brain tissue during resection surgery. The standard of care, which is interpreted as the surgeon's perception of cancer

based on gross appearance and all available intraoperative surgical navigational systems, has shown to have 100% sensitivity and 40% to 50% specificity (7). Overcoming this surgical challenge will enable both maximizing cancer resection and minimizing damage of healthy brain tissue, thus significantly improving both the overall survival rate (OS) and progression-free survival (PFS; refs. 8–10). Several imaging techniques are currently being evaluated or already adopted as image-guided surgical tools to assist with brain cancer resection. MRI provides excellent visualization of soft tissue, but it is not sensitive at detecting microscopic diseases at tumor margin, even when used intraoperatively (11). Intraoperative CT (iCT) allows assessing for residual cancer, but has low resolution at the tumor periphery (12). In addition, these imaging modalities are time-consuming, costly (upwards of \$1 million dollars to adopt), and do not provide continuous real-time intraoperative guidance. Intraoperative ultrasound imaging (iUS) enables real-time imaging, but it has limited contrast and spatial resolution for brain cancer detection (13). Intraoperative fluorescence imaging of 5-aminolevulinic acid (5-ALA) induced protoporphyrin-IX (PpIX) has shown a good correlation between fluorescence distribution and the presence of high-grade glioma (14), but it has shown limited sensitivity and specificity for detecting cancer-infiltrated brain tissue and low-grade gliomas (15, 16). Raman spectroscopy and imaging have been broadly applied for brain tissue biochemical differentiation (17) and glioma infiltration detection by

¹Department of Biomedical Engineering, Texas A&M University, College Station, Texas. ²Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland. ³Department of Neurologic Surgery, Mayo Clinic, Jacksonville, Florida. ⁴Facultad de Ciencias, Universidad Autónoma de San Luis de Potosí, San Luis de Potosí, Mexico. ⁵Division of Neuropathology, Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland. ⁶School of Electrical and Computer Engineering, University of Oklahoma, Norman, Oklahoma.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Javier A. Jo, University of Oklahoma, Stephenson Research and Technology Center, Suite 1108, 101 David L. Boren Blvd., Norman, OK 73019. Phone: (405) 325-9600; Fax: (405) 325-6029; E-mail: javierjo@ou.edu

Clin Cancer Res 2019;25:6329–38

doi: 10.1158/1078-0432.CCR-19-0854

©2019 American Association for Cancer Research.

Translational Relevance

Maximal tumor resection improves overall survival and delays cancer recurrence in patients with glioma; however, the margins of highly infiltrating gliomas are often very difficult to delineate during glioma resection surgery. Various medical imaging modalities are used pre- and/or intraoperatively to assist in the delineation of glioma margins. Unfortunately, none of these technologies can provide quantitative, real-time, accurate, and continuous guidance during glioma resection surgery. Optical coherence tomography (OCT) is a noninvasive, label-free, real-time, high-resolution volumetric imaging modality. Previous computational methods for OCT-based detection of glioma infiltration require sacrificing significantly spatial resolution and performing cumbersome calibration procedures. We have developed and validated an alternative accurate and fast artificial intelligence (AI)-assisted computational method that overcomes these major limitations. Our method can be implemented within generic OCT instruments to enable real-time, high-resolution, automated, accurate, *in situ*, intraoperative detection of glioma infiltration, facilitating maximal tumor resection and improved surgical outcomes for patients with glioma.

providing subcellular resolution and label-free imaging capabilities (18–22). Unfortunately, several limitations are associated to these techniques, including the intrinsic weakness of the Raman signal, limited imaging depth and field of view (FOV), and slow imaging speed (23–25). In addition, the capability of Raman spectroscopy and/or imaging for detecting cancer-infiltrated brain tissue intraoperatively has not yet fully demonstrated (26, 27). More recently, coherent Raman Scattering (CRS) and Stimulated Raman Scattering Microscopy (SRS) have been explored for brain tumor margin differentiation; however, a definite intraoperative computer-aided diagnosis (CAD) system for human brain tissue differentiation has not been reported (23, 26, 28, 29). In summary, there is still an urgent need for image-guided tools capable of providing continuous, *in situ* and accurate assessment of brain cancer infiltration during brain tumor resection surgery.

Optical coherence tomography (OCT) is a noninvasive medical imaging technique capable of continuous, label-free, high-resolution, 2D and 3D imaging of biological tissues (30). Because the imaging depth of OCT (1.5–3 mm) is similar to the resection depth of cancer-infiltrated brain regions, OCT has been evaluated as an image-guided tool for brain tumor resection surgery (7, 31–35). One common limitation of previous studies, however, is the lack of adequate computational methods for rapid, automated, and accurate intraoperative detection of cancer-infiltrated brain tissue at high spatial resolution, particularly for glioma resection.

Previous computational methods for OCT-based detection of glioma-infiltrated brain tissue rely on estimating the tissue optical attenuation coefficient from the OCT signal, which require averaging multiple A-line signals to reduce the noise and thus sacrificing spatial resolution. In addition, previous methods also require performing calibration procedures using tissue phantoms (7, 31, 33, 36). To overcome these major challenges, we have developed a novel artificial intelligence (AI)-based computational method in which each depth-dependent OCT intensity

measurement (or A-line) is modeled as a linear combination of underlying characteristic intensity-depth profiles. As a result, this method enables identifying and quantifying intensity-depth signatures specific to A-lines from glioma-infiltrated brain tissue, which can be utilized as discriminative features within machine learning algorithms to detect glioma-infiltrated brain tissue. The method was successfully developed using a database of OCT 3D images taken from freshly resected human noncancerous and glioma-infiltrated brain tissue samples, and its performance was robustly quantified using an independent validation database. Owing to its demonstrated accuracy, low computational cost, and high spatial resolution, this method has the potential to enable the development of OCT-guided surgical tools for continuous, real-time, and accurate *in situ* intraoperative detection of glioma infiltration.

Materials and Methods

Database of OCT scans from fresh brain tissue surgical samples

Intraoperative, fresh brain tissue samples were obtained from the edge of the surgical cavity based on neurosurgeon visual interpretation and image-guided navigation in 21 surgical glioma patients. The imaging protocol was approved by the Institutional Review Board at Johns Hopkins University (Baltimore, MD), which follows the Belmont Report ethical guidelines. Informed written consent was obtained from each subject or each subject's legal guardian. The tissue samples corresponded to either noncancerous or glioma-infiltrated brain regions. A number of OCT volumes were acquired from different locations within each brain tissue sample. The measured OCT lateral (i.e., horizontal) and axial (i.e., vertical or depth) resolutions were approximately 16.0 μm and 6.4 μm (in tissue), respectively (7). Each volume consists of a series of 10 OCT cross-sectional images or B-scans of 1,024 pixels (2 mm) laterally by 2,048 pixels (2.5 mm) in depth, where each B-scan was acquired at 0.5-mm intervals, resulting in a volume of $5 \times 2 \times 2.5 \text{ mm}^3$ ($W \times L \times D$). To divide the database of OCT volumes into training and validation sets, the 21 patients were randomly divided into two groups, one with 12 and another with 9 patients. All the volumes from the group of 12 patients were assigned to the training set, while all the volumes from the group of 9 patients were assigned to the validation set. All the samples underwent histopathologic processing and evaluation by a neuropathologist (7). The histopathologic distributions of the OCT volumes in the training and validation sets are summarized in Table 1.

OCT B-scans preprocessing

Each original OCT B-scan was preprocessed following the procedure described in Fig. 1. First, the original B-scan (Fig. 1A) was cropped to remove artifacts from above the tissue surface using a predefined fixed crop (Fig. 1B). Then, the tissue surface was detected from the cropped B-scan using the Canny Edge Detection algorithm (Fig. 1C; ref. 37), and the B-scan was warped using a circle-shifting upward method to flatten the surface (Fig. 1D). Finally, to eliminate reflection artifacts within the tissue region caused by the cover glass or the saline surface (Fig. 1D, arrows), a peak detection algorithm was applied and the regions of the A-line around the detected peaks were smoothed using a 2D entropy filter of order 5×5 . Although, these preprocessing steps do not guarantee the absolute elimination of all artifacts, the resulting preprocessed B-scans (Fig. 1E) were

Table 1. Training set (12 patients, 194 OCT volumes, 1,940 B-scans) and validation set (9 patients, 295 OCT volumes, 2,950 B-scans)

Patient #	Location	# Noncancerous OCT volumes	# Glioma-infiltrated OCT volumes	Grade of cancer
Training set				
Patient-1	1A	3	—	—
Patient-2	2A	4	—	—
Patient-3	3A	3	—	—
Patient-4	4A	13	—	—
	4B	8	—	—
Patient-5	5A	10	—	—
Patient-6	6A	—	8	Grade II
	6B	—	9	Grade II
	6C	—	11	Grade II
	6D	—	13	Grade II
Patient-7	7E	—	16	Grade II
	7A	—	5	Grade II
Patient-8	7B	—	11	Grade II
	8A	—	8	Grade II
Patient-9	8B	—	10	Grade II
	8C	—	11	Grade II
	9A	18	—	—
Patient-10	10A	—	5	Grade IV
	10B	—	5	Grade IV
	10C	—	5	Grade IV
Patient-11	11A	—	8	Grade IV
Patient-12	12A	10	—	—
Total in training set		69	125	
Validation set				
Patient-13	13A	—	13	Grade II
	13B	—	17	Grade II
	13C	—	14	Grade II
Patient-14	14A	18	—	—
Patient-15	15A	15	—	—
	15B	9	—	—
	15C	9	—	—
Patient-16	16A	16	—	—
	16B	8	—	—
	16C	16	—	—
Patient-17	17A	23	—	—
	17B	16	—	—
Patient-18	18A	21	—	—
Patient-19	19A	—	22	Grade IV
	19B	—	14	Grade IV
Patient-20	20A	12	—	—
	20B	—	17	Grade II
Patient-21	21A	5	—	—
	21B	—	15	Grade IV
	21C	—	15	Grade IV
Total in validation set		168	127	

adequate for the application of the A-line modeling method described in the following section.

Model-based OCT A-line feature extraction

The main idea behind our method for automated classification of noncancerous versus glioma-infiltrated brain regions is to model every A-line y_k of any OCT B-scan as a linear combination of N profiles or end-members p_n ($n = 1, \dots, N$):

$$y_k = \sum_{n=1}^N \alpha_{k,n} p_n \quad \forall k = 1, \dots, K. \quad (\text{A})$$

The profiles p_n are assumed to be the same for all the A-lines of the available data, while the linear coefficients or abundances $\alpha_{k,n}$, are assumed to be unique to each A-line y_k . The profiles p_n

were first estimated from the training set, consisting of 1,940 B-scans (Table 1). To accelerate the estimation of the profiles, only every other A-line in each B-scan of the training set were used (512 out of 1,024 A-lines per B-scan). All the selected training A-lines ($1,940 \times 512 = 993,280$) were arranged into a matrix $Y = [y_1 \dots y_K]$ of size $L \times K$, where L is the length of each A-line (1,024) and K is the total number of A-lines in the training set (993,280). The N unknown profiles p_n were arranged into a matrix $P = [p_1 \dots p_N]$ of size $L \times N$, where L is the length of each profile (equal to the A-line length) and N is the number of profiles. The unknown abundances were arranged into a matrix $A = [\alpha_1 \dots \alpha_K]$ of size $N \times K$, respectively, where the abundance column vector at the k^{th} A-line is denoted as $\alpha_k = [\alpha_{k,1} \dots \alpha_{k,N}]^T$. Using this matrix notation, the modeling of all the A-lines, based on Eq. (A), can be expressed as: $Y = PA$.

The simultaneous estimation of the unknown profile P and abundance A matrices from the training OCT A-line data Y can be formulated as a nonlinear quadratic optimization problem, with the following specific constrains: (i) the profiles can have positive values only ($P \geq 0$), (ii) the abundances can have positive values only ($A \geq 0$), and (iii) the values of the abundances for a given A-line should add to one, since they represent the relative contribution of each profile to that A-line ($A^T \mathbf{1} = 1$). The resolution of this constrained nonlinear quadratic optimization problem can be performed by applying our recently developed and validated blind end-member and abundance estimation (BEAE) method (38, 39), which minimizes the following cost function:


$$\min_{P,A} \frac{1}{2} \|Y - PA\|_F^2 + \rho \sum_{i=1}^{N-1} \sum_{j=i+1}^N \|p_i - p_j\|^2 - \mu \|A\|_F^2. \quad (\text{B})$$

The first term is directly related to the quadratic optimization approach in Eq. (A). The second term is a regularization term that penalizes the distance between profiles by using a regularization parameter $\rho > 0$. The third term is a regularization parameter for the abundances that ensures low entropy conditions among A-lines by using $\mu > 0$. Once the profiles P have been estimated from the training data, the abundances for any new set of A-lines can be directly estimated by solving Eq. (A) using a constrained linear least square approach. This estimation is computationally fast, as it only involves solving a system of linear equations with positivity constrain on the abundances.

Classifier training

The abundances $\alpha_{k,n}$ estimated for each A-line can be used as discriminative features within a machine learning algorithm designed to classify each A-line as from either a noncancerous or a glioma-infiltrated brain region. Because of the number of features ($N - 1$) versus the number of training data (K), a simple logistic regression classifier was chosen over other more complex methods, such as support-vector machines and neural networks (40). Because each whole OCT volume in the training set was annotated as either noncancerous or glioma-infiltrated brain tissue (Table 1), all the A-lines in a given volume were labeled based on their volume annotation. The resulting abundances A from the 993,280 labeled A-lines in the training set (194 volumes \times 10 B-Scans/volume \times 512 A-lines/B-Scan, see Table 1) were then used to optimize the logistic regression classifier. Because the logistic regression

Juarez-Chambi et al.

**Figure 1.**

Preprocessing steps applied to every B-scan in both the training and validation sets. **A**, Unprocessed B-scan. **B**, Cropped B-scan. **C**, Surface detection using the Canny Edge Detection algorithm. **D**, Warped B-scan to generate a flat surface. **E**, Peak detection to identify locations of reflection artifacts and entropy filtering around the detected peaks to obtain a completely preprocessed B-scan. **F**, Results of the BEAE analysis applied to the training set. Top, all the A-lines (Y) from the training set included in the BEAE analysis. Middle, Estimated abundances (A) for each A-line analyzed. Bottom, estimated profiles (P) common to all the A-lines included in the BEAE analysis. **G**, Sample A-line from a noncancerous volume and its fit modeled as the linear combination of the estimated common profiles (P). **H**, Sample A-line from a glioma-infiltrated volume and its fit modeled as the linear combination of the estimated common profiles (P).

classifier was trained to classify each A-line of a new OCT volume as either from a noncancerous or a glioma-infiltrated brain region, not all the A-lines from the new OCT volume would necessarily be classified to the same class. Therefore, to classify a whole new OCT volume as either from a noncancerous or a glioma-infiltrated brain region, a threshold on the

percentage of A-lines classified as from a glioma-infiltrated region in that volume was used. This threshold was determined by performing a ROC analysis following a Leave-One-Patient-Out-Cross-Validation (LOPOCV) classification performance estimation strategy with the OCT volumes of the training set.

Classification performance estimation

The overall machine learning classification computational scheme optimized with the training set was applied to the validation set. First, the same profiles P estimated from the training set were used to directly estimate the abundances of each of the A-lines in the validation set. Then, the resulting abundances A from the 3,020,800 A-lines in the validation set ($295 \text{ volumes} \times 10 \text{ B-Scans/volume} \times 1,024 \text{ A-lines/B-Scan}$, see Table 1) were used to classify each A-line as either from a noncancerous or a glioma-infiltrated brain region using the same logistic regression classifier optimized with the training set. Finally, each of the 295 OCT volumes in the validation set were classified as either from a noncancerous or a glioma-infiltrated brain region using the same threshold on the volume percentage of A-lines classified as from a glioma-infiltrated region, previously optimized with the training set. The classification performance obtained from the validation set was quantified in terms of overall classification accuracy, sensitivity, and specificity.

Results

OCT A-line model performance


The BEAE method was applied using a model order of $n = 3$ (number of profiles) to the A-lines of the OCT volumes in the training set, as illustrated in (Fig. 1F). A detailed description of the method used to determine the optimal BEAE order value of $n = 3$ is provided as Supplementary Material. All the 1,940 B-scans analyzed are shown stacked up next to each other horizontally in the top panel. No clear distinction between A-lines from

noncancerous and glioma-infiltrated brain regions (separated by the red dashed line) can be observed from the stacked B-scans. The estimated abundances A of the 993,280 A-lines from the training set included in the BEAE analysis are shown in the middle panel. The three profiles P estimated from the training set, shown in the bottom panel, have complementary shapes and positive amplitude values as expected due to the positivity optimization constrain. To illustrate the capability of the BEAE method to model A-lines as a linear combination of the three estimated common profiles (P), sample A-lines and their model fits are shown in (Fig. 1G) (noncancerous volume) and (Fig. 1H; glioma-infiltrated volume). It can be observed that the model fits capture the shape of the A-line without overfitting the noise in the OCT signal.

Model-based OCT A-line feature extraction

An important consequence of modeling any A-line γ_k as a linear combination of a set of common profiles p_n is the resulting unique representation of each A-line in terms of its abundances $\alpha_{k,n}$. Because these unique sets of abundances parameterize the unique shape of each A-line, they can be utilized as feature vectors within a machine learning classification algorithm. Because the abundances of each A-line add to 1, only $(N-1)$ abundances are independent. Because the OCT training A-lines were modeled using three abundances ($N = 3$), only two of them could be used as classification features. The distributions of each of the three abundances for the noncancerous and glioma-infiltrated A-lines from the training set are shown in (Fig. 2). It can be observed that the first abundance is

Figure 2. Distributions of the three abundances of the noncancerous and glioma-infiltrated A-lines in the training set. **A**, The first abundance ($\alpha_{k,1}$) is distributed at lower values for the glioma-infiltrated A-lines. **B**, The distribution of the second abundance ($\alpha_{k,2}$) roughly mirrors that of the first abundance. **C**, The third abundance ($\alpha_{k,3}$) is distributed at higher values for the glioma-infiltrated A-lines. **D**, Distributions of the feature vectors $x_k = [\alpha_{k,1}, \alpha_{k,3}]$ for the noncancerous and glioma-infiltrated A-lines (only 0.02% of the total training set is shown for clarity).



distributed at lower values for the glioma-infiltrated A-lines (Fig. 2A), while the opposite can be observed for the third abundance (Fig. 2C). In addition, the distributions of the first and second abundances are roughly the reflection of each other, providing redundant information (Fig. 2A and B). Following an exhaustive feature selection approach, the first and third abundances ($\alpha_{k,1}$, $\alpha_{k,3}$) were chosen for the optimal feature vector $x_k = [\alpha_{k,1}, \alpha_{k,3}]$ used for training the logistic regression classifier aiming to identify an A-line as either from a noncancerous or a glioma-infiltrated brain region. In Fig. 2D, the distributions of these feature vectors for the noncancerous and glioma-infiltrated A-lines of the training set are shown in the two-dimensional space ($\alpha_{k,1}$, $\alpha_{k,3}$). A detailed description of the method used for feature selection is provided as Supplementary Material.

Classifier training

The logistic regression classifier was trained to classify any A-line as either from a noncancerous or a glioma-infiltrated brain region using the 194 OCT volumes in the training set. To classify a whole new OCT volume as either noncancerous or glioma-infiltrated, the threshold on the percentage of A-lines classified as from a glioma-infiltrated region in that volume was determined by applying ROC analysis following a LOPOCV performance estimation strategy in all the 194 OCT volumes of the training set. The corresponding area under the ROC curve (AUC) was $AUC = 0.96$, which indicates a very promising classification performance. Because the clinical emphasis is to obtain maximal glioma-infiltrated tissue resection while preserving as much healthy tissue as possible, sensitivity for detecting glioma-infiltrated tissue was prioritized over specificity. A threshold of 80% was selected to maximize the sensitivity for detecting glioma-infiltrated region (99.15%) while maintaining as much noncancerous tissue as possible (86.21%). The results of the ROC analysis are shown in (Fig. 3A).

Classification performance estimation

The performance of the trained logistic regression classifier was estimated blindly on the totally independent validation set as follows. First, the abundances of each A-line in the validation set were estimated using the same profiles already estimated from the training set (Fig. 1F, bottom). The abundance estimation is computationally fast, due to the matrix operation approach, allowing computing a B-Scan (1024 A-lines) in 30 milliseconds using MATLAB in a Core i7 4790K 4 GHz processor. Once the abundances have been estimated, each A-line in the validation set was classified using the independently trained logistic regression classifier. After the A-line level classification, each OCT volume was finally classified as either from a noncancerous or a glioma-infiltrated region using the previously selected threshold on the percentage of A-lines in that volume classified as from a glioma-infiltrated region. The results on the classification of the OCT volumes in the validation set are summarized in Table 2. The applied double-blinded validation indicated promising levels of sensitivity (>90%) and specificity (>80%) for discriminating low-grade and/or high-grade glioma-infiltrated tissue from noncancerous tissue. Nevertheless, approximately 15% of all volumes were misclassified, probably due to significant intra-class variability and extra-class similarity observed among the OCT images, as illustrated in (Fig. 3B–E). It is worth noting that this validation set was completely independent (collected from 9 different patients) and the validation was blindly

performed, meaning that the validation set was provided unlabeled for the described performance estimation procedure.

To demonstrate the potential of our computational framework for real-time accurate detection and volumetric visualization of cancerous and noncancerous brain tissue, two unlabeled high-resolution OCT volumes ($5 \times 2 \times 2.5 \text{ mm}^3$; $256 \times 2,048 \times 2,048$ pixels) from a noncancerous and a glioma-infiltrated brain region were blindly processed with our trained computational framework. The computational speed for processing and classifying each A-line was >100,000 A-lines per second. To visualize the classification results, the OCT volumetric data was 3D rendered, and the surface of the imaged brain region was color-coded using a colormap proportional to the estimated post-probability of each A-line being from a glioma-infiltrated brain region (Fig. 3F). For the OCT volume of a glioma-infiltrated brain region (Fig. 3F, left), 100 % of the A-lines were correctly classified as from glioma-infiltrated brain region. For the OCT volume of a noncancerous brain region (Fig. 3F, right), 92 % of the A-lines were correctly classified as from noncancerous brain region.

Discussion

Maximal tumor resection both improves the overall survival and delays cancer recurrence in patients with low-grade and high-grade glioma (6, 41–43). The limited ability of neurosurgeons to differentiate noncancerous versus cancer-infiltrated brain tissues during resection surgery is the main challenge preventing higher rates of maximal tumor resection. Although several imaging techniques have been utilized routinely to assist brain cancer surgeries (7, 13, 29, 44, 45), there are significant limitations to these modalities. An effective image-guided tool for brain cancer resection surgery should be capable of providing high-resolution, accurate, continuous, and real-time *in situ* discrimination between noncancerous and cancer-infiltrated brain tissue from intraoperative volumetric brain images.

Optical imaging modalities are well suited to enable such capabilities. Among them, intraoperative imaging of 5-ALA-induced PpIX brain tissue fluorescence is perhaps the most extensively evaluated approach. Unfortunately, its performance for identifying glioma-infiltrated brain regions has not been fully demonstrated, with different studies reporting a wide range of sensitivity (50%–100%) and specificity (70%–100%; ref. 46). One major limitation of this approach is its dependency on the sufficient and specific 5-ALA uptake by the glioma tissue, which can be affected by many factors, including blood–brain barrier permeability, cellular/vascular proliferation, and glioma grade (16, 47). Another limitation is the lack of quantitative methods to image the 5-ALA-induced PpIX fluorescence, which has prevented successfully moving from a subjective to a more objective and accurate interpretation of 5-ALA-induced PpIX brain tissue fluorescence images (48).

OCT can be seemingly implemented as a hand-held surgical tool and/or integrated into standard surgical microscopes to provide label-free, high-resolution, and fast volumetric tissue imaging. These capabilities and its relatively inexpensive implementation cost make OCT an ideal imaging modality to enable continuous real-time guidance during brain cancer resection surgery. However, for OCT to become an impactful image-guided tool for brain cancer resection surgery, CAD systems are needed to enable *in situ* intraoperative automated, objective, and accurate detection of cancer-infiltrated brain tissue, as well as real-




Figure 3.

A. Results of the ROC analysis performed on the training set to select the threshold in the volume percentage of A-lines classified as from a glioma-infiltrated region used to classify the whole volume as either from a noncancerous or a glioma-infiltrated region. The AUC = 0.96 indicates a very promising classification performance. A threshold of 80% was selected to maximize the sensitivity (99.15%) at the best specificity level possible (86.21%) for classifying volumes from a glioma-infiltrated region. Sample classified B-scans from the validation set, in which the surface was color-coded based on each A-line classification (red: glioma-infiltrated; green: noncancerous): true positive (**B**), false positive (**C**), false negative (**D**), and true negative (**E**). **F.** Sample OCT 3D rendered images of brain regions in which the surface of the imaged brain tissue is color-coded using a colormap proportional to the estimated post-probability of each A-line being from a glioma-infiltrated brain region. For the sample OCT volume of a glioma-infiltrated brain region (left), 100% of the A-lines were correctly classified as from glioma-infiltrated brain region. For the sample OCT volume of a noncancerous brain region (right), 92% of the A-lines were correctly classified as from noncancerous brain region.

time volumetric visualization of cancerous and noncancerous brain tissue during tumor resection surgery.

Previously reported approaches for OCT-based detection of cancer-infiltrated brain tissue rely on estimating the tissue optical attenuation coefficient from the OCT signal, which is

used as a discriminative feature for identifying cancerous or cancer-infiltrated brain tissue (7, 34, 49). For instance, Kut and colleagues recently introduced a computationally efficient method to estimate the optical attenuation coefficient of brain tissue from OCT scans, and demonstrated the potential of this

Table 2. Confusion matrix of the blind validation classification results

Predicted	Low-grade vs. noncancerous		High-grade vs. noncancerous		Low/high-grade vs. noncancerous	
	Sensitivity 90.16%	Specificity 80.95%	Sensitivity 95.45%	Specificity 82.14%	Sensitivity 90.55%	Specificity 82.73%
+	55	32	63	30	115	29
-	6	136	3	138	12	139

NOTE: Left column, results for the classification of low-grade glioma-infiltrated versus noncancerous brain tissue; middle, results for the classification of high-grade glioma-infiltrated versus noncancerous brain tissue; right column, results for the classification of low/high-grade glioma-infiltrated versus noncancerous brain tissue. OCT volumes were predicted as being either positive (+) or negative (-) for the presence of glioma infiltration.

estimated optical parameter to detect glioma-infiltrated brain tissue (sensitivity $\sim 90\%$, specificity $\sim 80\%$) using an independent validation set of 59 brain tissue samples (7).

One major limitation of all these OCT quantitative methods, however, is the need to spatially average neighboring OCT A-lines to attain signal-to-noise ratio levels that are adequate for estimating the tissue optical attenuation coefficient. For example, in the study by Kut and colleagues, a B-scan of 1024 A-lines was divided in three adjacent regions, and all the ~ 341 A-lines in each region were averaged to estimate three optical attenuation coefficient values per B-scan; thus, only three regions per B-scan could be classified using their approach (7). In contrast, A-line averaging is not needed in our method; thus, each A-line can be classified, resulting in an improvement in spatial resolution of $\sim 341:1$ compared to the method by Kut and colleagues (7). Moreover, because the spatial resolution of the classification map provided by our method is equal to the lateral optical resolution of the OCT instrument used (16.0 μm for this study), the resolution of the classification map can be as good as the best optical resolution possible with the available state-of-the-art OCT instrumentation technology. The demonstrated superior spatial resolution enabled by our method is particularly relevant for the accurate detection of glioma-infiltrated brain tissue, which is characterized by showing a wide range in the degree of cancer infiltration at the tumor margins.

Furthermore, the previously reported approaches for OCT-based detection of cancer-infiltrated brain tissue, including the method by Kut and colleagues (7), is the need to perform calibration procedures that could be cumbersome. In comparison, our method reported here only requires a training set of labeled OCT brain tissue scans obtained with the same or a similar OCT instrument to estimate the depth profiles p_n used to model each A-line and train the logistic regression classifier.

The classification performance of our computational framework for detecting glioma-infiltrated brain tissue (sensitivity: $>90\%$; specificity: $>82\%$) was quantified following a robust and unbiased double-blinded validation strategy using an independent validation set of 295 brain tissue samples. Moreover, the methods adopted at each stage of our computational framework (preprocessing, feature extraction, classification) were also strategically chosen and designed to enable real-time processing of OCT volumetric images. Thus, another relevant feature of our computational framework is its high processing speed (100,020 A-lines per second, using MATLAB in a Core i7 4790K 4 GHz processor), which would enable processing an arbitrary tissue volume of $5 \times 5 \times 2.5 \text{ mm}^3$ ($256 \times 256 \times 2,048$ pixels) in approximately 0.7 seconds. It should be noted that the processing speed of this novel computational framework can be significantly increased by implementing it using object-oriented programming languages and parallel programming and computing. Altogether, the demonstrated classification accuracy and processing speed of our computational framework, once embedded within intraoperative OCT imaging instruments, would enable developing clinically relevant CAD systems for automated, accurate, real-time *in situ* detection of glioma infiltration during tumor resection surgery.

Study limitations

Although the results of this preliminary study are quite encouraging, it still has some limitations. First, our com-

putational framework showed a misclassification rate of approximately 15%, in part, due to the noticed intra-class variability and extra-class similarity observed among the OCT images (Fig. 3B-E), which might indicate the need for using additional OCT features and/or more sophisticated classification methods. Furthermore, from the computational point of view, noisy labeling is expected in medical imaging data, and in our OCT brain tissue datasets, in particular, due to the heterogeneity of the glioma tissue samples. To overcome this problem, the use of classification methods with higher tolerance to noisy labels (e.g., weakly supervised learning models) might improve the performance of the model. Moreover, the current OCT databases, when analyzed at the A-line level, could be sufficiently large to allow exploring state-of-the-art classifiers such as those based on Convolutional Neural Networks (CNN), which might also improve the detection of glioma-infiltrated brain tissue.

In addition, it can be quite possible that a classification model designed and trained to detect infiltration of a specific tumor type and grade could outperform a more general model designed and trained to detect infiltration of a plurality of brain tumor types and/or grades. To investigate this alternative approach, two additional classification models were trained using either the available low-grade or high-grade glioma-infiltrated samples, and their results are reported as Supplementary Material.

Compared with the original more general classification model, these more targeted classifiers performed with lower sensitivity but better specificity. These observations suggest that once more comprehensive databases become available, more specific classification models can be developed and compared against more general ones to determine an optimal approach.

Another limitation is that the OCT datasets used for training and validating our computational framework were acquired from freshly resected noncancerous, low-grade glioma-infiltrated and high-grade glioma-infiltrated brain tissue samples from glioma patients undergoing tumor resection surgery. Because the training and validation datasets used in this study cannot be considered representative of the "universe" of tumor, the training of our computational framework needs to be repeated using more comprehensive databases of *in vivo* OCT volumes that include other tumor types. Once optimized, the computational framework would be embedded into an intraoperative OCT imaging instrument, and the performance of the resulting OCT-guided surgical tool for automated real-time *in situ* intraoperative detection of brain tumor infiltration will have to be quantified in a prospective clinical study, as depicted in Fig. 4.

Conclusions

In conclusion, we have introduced a novel computational method for OCT-based automated detection of glioma-infiltrated from noncancerous brain tissue. Our method applies a modeling approach to parametrize the information encoded in the shape of each depth-dependent OCT intensity signal (A-line) and uses the A-line model parameters as features within a machine learning classification scheme. Because our method can process OCT images at their original high spatial resolution and does not require performing calibration procedures using tissue




Figure 4.

Methodology for an OCT-based CAD system. **A**, After a preoperative MRI for evaluation, we will use a OCT probe (**B**) for intraoperatively image guidance during surgery (**C**). Finally, after preprocessing, feature extraction and classification (**D**), the automated real-time classification using a volumetric color-coded map of the tissue will be displayed for real-time guidance.

phantoms, it overcomes major challenges of previously reported methods. Because of its demonstrated detection accuracy, robustness and low computational cost, this method could enable developing faster, and more accurate OCT-guided surgical tools for continuous, real-time and accurate *in situ* intraoperative detection of any stage glioma infiltration, facilitating extensive glioma resection and improved surgical outcomes for patients with glioma.

Disclosure of Potential Conflicts of Interest

X. Li reports receiving commercial research grants from MicroTech LLC, holds ownership interest (or patents) in Insight Photonics and MicroTech LLC, and is a consultant/advisory board member for SIBET, Chinese Academy of Science. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: R.M. Juarez-Chambi, J.J. Rico-Jimenez, J. Xi, A. Quinones-Hinojosa, X. Li, J.A. Jo

Development of methodology: R.M. Juarez-Chambi, J.J. Rico-Jimenez, K.L. Chaichana, J. Xi

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. Kut, F.J. Rodriguez, A. Quinones-Hinojosa, X. Li, J.A. Jo

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R.M. Juarez-Chambi, C. Kut, K.L. Chaichana, A. Quinones-Hinojosa, X. Li, J.A. Jo

Writing, review, and/or revision of the manuscript: R.M. Juarez-Chambi, C. Kut, J.J. Rico-Jimenez, K.L. Chaichana, F.J. Rodriguez, A. Quinones-Hinojosa, X. Li, J.A. Jo

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R.M. Juarez-Chambi, X. Li

Study supervision: X. Li, J.A. Jo

Other (design of BEAE modeling): D.U. Campos-Delgado

Acknowledgments

This research was partially supported by grants from the NIH (grants R01CA218739, R01CA200399), the Cancer Prevention and Research Institute of Texas (grant RP180588), the Coulter H. Wallace Foundation, NSF-NCSA XSEDE ASC170017, FONDECYT-CONCYTEC Fellowship. A. Quinones-Hinojosa acknowledged the support by the William J. and Charles H. Mayo Professorship and a Mayo Clinician Investigator award. K.L. Chaichana acknowledged the support by the Mayo RACER award.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 14, 2019; revised May 24, 2019; accepted July 12, 2019; published first July 17, 2019.

References

- Almeida JP, Chaichana KL, Rincon-Torroella J, Quinones-Hinojosa A. The value of extent of resection of glioblastomas: clinical evidence and current approach. *Curr Neurol Neurosci Rep* 2015;15:517.
- Marko NF, Weil RJ, Schroeder JL, Lang FF, Suki D, Sawaya RE. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. *J Clin Oncol* 2014;32:774–82.
- Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J, et al. Multiple resections for patients with glioblastoma: prolonging survival. *J Neurosurg* 2013;118:812–20.
- Lara-Velazquez M, Al-Kharboosh R, Jeanneret S, Vazquez-Ramos C, Mahato D, Tavanaiepour D, et al. Advances in brain tumor surgery for glioblastoma in adults. *Brain Sci* 2017;7. doi: 10.3390/brainsci7120166.
- Eseonu CI, Eguia F, ReFaey K, Garcia O, Rodriguez FJ, Chaichana K, et al. Comparative volumetric analysis of the extent of resection of molecularly and histologically distinct low grade gliomas and its role on survival. *J Neurooncol* 2017;134:65–74.
- Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I, Wijesekera O, Olivi A, Rahman M, et al. When gross total resection of a glioblastoma is possible, how much resection should be achieved? *World Neurosurg* 2014;82: E257–65.
- Kut C, Chaichana KL, Xi J, Raza SM, Ye X, McVeigh ER, et al. Detection of human brain cancer infiltration *ex vivo* and *in vivo* using quantitative optical coherence tomography. *Sci Transl Med* 2015;7:292ra100.
- McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. *Neurosurgery* 2009;65:463–9.
- Chaichana KL, Jusue-Torres I, Lemos AM, Gokaslan A, Cabrera-Aldana EE, Ashary A, et al. The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors? *J Neurooncol* 2014; 120:625–34.
- Rahman M, Abbatematteo J, De Leo EK, Kubilis PS, Vaziri S, Bova F, et al. The effects of new or worsened postoperative neurological deficits

- on survival of patients with glioblastoma. *J Neurosurg* 2017;127:123–31.
11. Mehranian A, Arabi H, Zaidi H. Quantitative analysis of MRI-guided attenuation correction techniques in time-of-flight brain PET/MRI. *Neuroimage* 2016;130:123–33.
 12. Spivak CJ, Pirouzmand F. Comparison of the reliability of brain lesion localization when using traditional and stereotactic image-guided techniques: a prospective study. *J Neurosurg* 2005;103:424–7.
 13. Rygh OM, Selbekk T, Torp SH, Lydersen S, Hernes TA, Unsgaard G. Comparison of navigated 3D ultrasound findings with histopathology in subsequent phases of glioblastoma resection. *Acta Neurochir* 2008;150:1033–41.
 14. Valdes PA, Kim A, Brantsch M, Niu C, Moses ZB, Tosteson TD, et al. delta-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. *Neuro Oncol* 2011;13:846–56.
 15. Ando T, Kobayashi E, Liao H, Maruyama T, Muragaki Y, Iseki H, et al. Precise comparison of protoporphyrin IX fluorescence spectra with pathological results for brain tumor tissue identification. *Brain Tumor Pathol* 2011;28:43–51.
 16. Montcel B, Mahieu-Willame L, Armoiry X, Meyronet D, Guyotat J. Two-peaked 5-ALA-induced PpIX fluorescence emission spectrum distinguishes glioblastomas from low grade gliomas and infiltrative component of glioblastomas. *Biomed Opt Express* 2013;4:548–58.
 17. Tashibu K. Analysis of water content in rat brain using Raman spectroscopy. *No To Shinkei* 1990;42:999–1004. [article in Japanese].
 18. Koljenovic S, Choo-Smith LP, Bakker Schut TC, Kros JM, van den Berge HJ, Puppels GJ. Discriminating vital tumor from necrotic tissue in human glioblastoma tissue samples by Raman spectroscopy. *Lab Invest* 2002;82:1265–77.
 19. Kalkanis SN, Kast RE, Rosenblum ML, Mikkelsen T, Yurglevic SM, Nelson KM, et al. Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections. *J Neurooncol* 2014;116:477–85.
 20. Kast R, Auner G, Yurglevic S, Broadbent B, Raghunathan A, Poisson LM, et al. Identification of regions of normal grey matter and white matter from pathologic glioblastoma and necrosis in frozen sections using Raman imaging. *J Neurooncol* 2015;125:287–95.
 21. Kast RE, Auner GW, Rosenblum ML, Mikkelsen T, Yurglevic SM, Raghunathan A, et al. Raman molecular imaging of brain frozen tissue sections. *J Neurooncol* 2014;120:55–62.
 22. Ji M, Orringer DA, Freudiger CW, Ramkissoon S, Liu X, Lau D, et al. Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. *Sci Transl Med* 2013;5:201ra119.
 23. Desroches J, Jermyn M, Pinto M, Picot F, Tremblay MA, Obaid S, et al. A new method using Raman spectroscopy for in vivo targeted brain cancer tissue biopsy. *Sci Rep* 2018;8:1792.
 24. Zhang J, Fan Y, He M, Ma X, Song Y, Liu M, et al. Accuracy of Raman spectroscopy in differentiating brain tumor from normal brain tissue. *Oncotarget* 2017;8:36824–31.
 25. Evans CL, Xu X, Kesari S, Xie XS, Wong ST, Young GS. Chemically-selective imaging of brain structures with CARS microscopy. *Opt Express* 2007;15:12076–87.
 26. Jermyn M, Mok K, Mercier J, Desroches J, Pichette J, Saint-Arnaud K, et al. Intraoperative brain cancer detection with Raman spectroscopy in humans. *Sci Transl Med* 2015;7:274ra19.
 27. Hollon TC, Lewis S, Pandian B, Niknafs YS, Garrard MR, Garton H, et al. Rapid intraoperative diagnosis of pediatric brain tumors using stimulated Raman histology. *Cancer Res* 2018;78:278–89.
 28. Fu Y, Huff TB, Wang HW, Wang H, Cheng JX. Ex vivo and in vivo imaging of myelin fibers in mouse brain by coherent anti-Stokes Raman scattering microscopy. *Opt Express* 2008;16:19396–409.
 29. Hollon T, Lewis S, Freudiger CW, Sunney Xie X, Orringer DA. Improving the accuracy of brain tumor surgery via Raman-based technology. *Neurosurg Focus* 2016;40:E9.
 30. Fujimoto JG, Pitris C, Bopp SA, Brezinski ME. Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy. *Neoplasia* 2000;2:9–25.
 31. Bopp SA, Brezinski ME, Pitris C, Fujimoto JG. Optical coherence tomography for neurosurgical imaging of human intracortical melanoma. *Neurosurgery* 1998;43:834–41.
 32. Chong SP, Merkle CW, Cooke DF, Zhang T, Radhakrishnan H, Krubitzer L, et al. Noninvasive, in vivo imaging of subcortical mouse brain regions with 1.7 μm optical coherence tomography. *Opt Lett* 2015;40:4911–4.
 33. Bohringer HJ, Lankenau E, Stellmacher F, Reusche E, Hüttmann G, Giese A. Imaging of human brain tumor tissue by near-infrared laser coherence tomography. *Acta Neurochir* 2009;151:507–17.
 34. Kut C, Xi J, Chaichana KL, Rincon-Torroella J, Rodríguez F, McVeigh E, et al. Real-time, label-free optical property mapping for detecting glioma invasion with SSOCOT for potential guidance of surgical intervention. Accepted for Oral Presentation at: 2015 SPIE Photonics West BIOS. February 2015. The Moscone Center, San Francisco, CA.
 35. Bohringer HJ, Boller D, Leppert J, Knopp U, Lankenau E, Reusche E, et al. Time-domain and spectral-domain optical coherence tomography in the analysis of brain tumor tissue. *Lasers Surg Med* 2006;38:588–97.
 36. Bizheva K, Unterhuber A, Hermann B, Povazay B, Sattmann H, Fercher AF, et al. Imaging ex vivo healthy and pathological human brain tissue with ultra-high-resolution optical coherence tomography. *J Biomed Opt* 2005;10:11006.
 37. Canny J. A computational approach to edge detection. *IEEE Trans Pattern Anal Mach Intell* 1986;8:679–98.
 38. Gutierrez-Navarro O, Campos-Delgado DU, Arce-Santana ER, Mendez MO, Jo JA. Blind end-member and abundance extraction for multispectral fluorescence lifetime imaging microscopy data. *IEEE J Biomed Health Inform* 2014;18:606–17.
 39. Rico-Jimenez JJ, Campos-Delgado DU, Villiger M, Otsuka K, Bouma BE, Jo JA. Automatic classification of atherosclerotic plaques imaged with intravascular OCT. *Biomed Opt Express* 2016;7:4069–85.
 40. Huang HH, Xu T, Yang J. Comparing logistic regression, support vector machines, and permanent classification methods in predicting hypertension. *BMC Proc* 2014;8:S96.
 41. Nickel K, Renovanz M, König J, Stöckelmaier L, Hickmann AK, Nadj-Ohl M, et al. The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients—results of a multicenter cross-sectional study. *Neurosurg Rev* 2018;41:207–19.
 42. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego M, Ibrahim A, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. *Neuro Oncol* 2014;16:113–22.
 43. Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. *Ann Surg Oncol* 2011;18:239–45.
 44. Petrecca K, Guiot MC, Panet-Raymond V, Souhami L. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. *J Neurooncol* 2013;111:19–23.
 45. Coburger J, Scheuerle A, Pala A, Thal D, Wirtz CR, König R. Histopathological insights on imaging results of intraoperative magnetic resonance imaging, 5-aminolevulinic acid, and intraoperative ultrasound in glioblastoma surgery. *Neurosurgery* 2017;81:165–74.
 46. Mansouri A, Mansouri S, Hachem LD, Klironomos G, Vogelbaum MA, Bernstein M, et al. The role of 5-aminolevulinic acid in enhancing surgery for high-grade glioma, its current boundaries, and future perspectives: a systematic review. *Cancer* 2016;122:2469–78.
 47. Utsuki S, Oka H, Sato S, Suzuki S, Shimizu S, Tanaka S, et al. Possibility of using laser spectroscopy for the intraoperative detection of nonfluorescing brain tumors and the boundaries of brain tumor infiltrates - technical note. *J Neurosurg* 2006;104:618–20.
 48. Cordova JS, Gurbani SS, Holder CA, Olson JJ, Schreiber E, Shi R, et al. Semi-automated volumetric and morphological assessment of glioblastoma resection with fluorescence-guided surgery. *Mol Imaging Biol* 2016;18:454–62.
 49. Yuan W, Kut C, Liang W, Li X. Robust and fast characterization of OCT-based optical attenuation using a novel frequency-domain algorithm for brain cancer detection. *Sci Rep* 2017;7:44909.

Clinical Cancer Research

AI-Assisted *In Situ* Detection of Human Glioma Infiltration Using a Novel Computational Method for Optical Coherence Tomography

Ronald M. Juarez-Chambi, Carmen Kut, Jose J. Rico-Jimenez, et al.

Clin Cancer Res 2019;25:6329-6338. Published OnlineFirst July 17, 2019.

Updated version Access the most recent version of this article at:
[doi:10.1158/1078-0432.CCR-19-0854](https://doi.org/10.1158/1078-0432.CCR-19-0854)

Supplementary Material Access the most recent supplemental material at:
<http://clincancerres.aacrjournals.org/content/suppl/2019/07/19/1078-0432.CCR-19-0854.DC1>

Cited articles This article cites 47 articles, 5 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/25/21/6329.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/25/21/6329>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.